NEOGENOMICS, INC. (NEO) FY2026 Q2 P&L / Income Statement

NEOGENOMICS, INC. (NEO) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

NET REVENUE

201,656,000 US dollars

COST OF REVENUE

109,778,000 US dollars

GROSS PROFIT

91,878,000 US dollars

Total operating expenses

101,649,000 US dollars

LOSS FROM OPERATIONS

negative 9,771,000 US dollars

Other income (expense), net (calculated)

11,597,000 US dollars

Income (loss) before taxes

1,826,000 US dollars

Income tax benefit

negative 412,000 US dollars

Net income (loss)

2,238,000 US dollars

Client direct billing

137,956,000 US dollars

Commercial insurance

36,273,000 US dollars

Medicare and other government

27,427,000 US dollars

Self-pay

0 US dollars

General and administrative

63,613,000 US dollars

Research and development

10,761,000 US dollars

Sales and marketing

27,275,000 US dollars

Impairment charges (Note 5)

0 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.